The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer
- PMID: 16541304
- DOI: 10.1007/s10549-006-9198-8
The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer
Abstract
Introduction: There is substantial evidence that breast cancer tissue contains all the enzymes responsible for the local biosynthesis of estrogens from circulating precursors. The cytochrome P-450 aromatase enzyme complex is responsible for the conversion of C19 androgens to estrogens and 17-beta-hydroxysteroid dehydrogenase (17-I(2)-HSD) type 1 catalyses the inter-conversion of estrone to the biologically more potent estradiol. The gene encoding for the cytochrome P-450 aromatase is known as CYP19 (15q21.2). It is well established that increased exposure to local estrogens is an important risk factor in the genesis and growth of breast cancer. The aim of this study is to investigate the relationship between CYP19 and 17-beta-HSD type 1A mRNA expression and clinico-pathological parameters of human breast cancer.
Methods: One hundred and twenty seven tumor tissues and 33 normal tissues were analyzed. The levels of transcription of CYP19 and 17-beta-HSD type 1 were determined using real-time quantitative PCR. The mRNA expression was normalized against CK19. Levels of expression were analyzed against tumorâ's stage, grade, nodal status, local relapse, distant metastasis and survival over a 120A months follow up period. In addition, the levels were analyzed against estrogen receptor (ER) and HER1-4 status.
Results: Overall, high tumor levels of mRNA expression of CYP19 and 17-beta-HSD type 1 correlated with poor survival (p=0.0105 and p=0.0182, respectively). Increased levels of CYP19 mRNA expression positively correlated with disease progression as levels were significantly higher in samples of patients who had distant metastasis and local recurrence and/or died of breast related causes when compared to those who were disease free for >10 years (p=0.0015). We also observed higher levels of CYP19 mRNA in tumor samples compared to normal breast tissue. However, this reached statistical significance only when comparing grade 1 tumors with normal tissue (p=0.01). There was no correlation between CYP19á mRNA expression and tumor stage, lymph node status and tumor grade. There was however a trend for a positive correlation between CYP19 and ER mRNA expressions (p=0.06). No significant difference in 17-beta-HSD type 1 expression between normal and cancerous tissues was observed. In tumor samples, we observed an increase in levels correlating with tumor's grade. This correlation was statistically significant when we compared grade 1 with grade 2 and grade 1 with grade 3 (p=0.0031 and 0.0251, respectively).
Conclusion: Our study shows that higher levels of the enzymes responsible for the local biosynthesis of estrogens especially aromatase are associated with a poor clinical outcome in patients with breast cancer.
Similar articles
-
The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.Anticancer Res. 2006 Nov-Dec;26(6C):4985-90. Anticancer Res. 2006. PMID: 17214375
-
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.Cancer Lett. 2006 Nov 8;243(1):23-31. doi: 10.1016/j.canlet.2005.11.010. Epub 2006 Mar 23. Cancer Lett. 2006. PMID: 16556483
-
Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.Cancer Res. 2001 Dec 1;61(23):8448-51. Cancer Res. 2001. PMID: 11731426
-
Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):221-36. doi: 10.1016/j.jsbmb.2005.02.007. J Steroid Biochem Mol Biol. 2005. PMID: 15860265 Review.
-
Oestrogen producing enzymes and mammary carcinogenesis: a review.Breast Cancer Res Treat. 2008 Sep;111(2):191-202. doi: 10.1007/s10549-007-9788-0. Epub 2007 Oct 13. Breast Cancer Res Treat. 2008. PMID: 17934808 Review.
Cited by
-
17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.Breast Cancer Res. 2012 Jun 12;14(3):R92. doi: 10.1186/bcr3207. Breast Cancer Res. 2012. PMID: 22691413 Free PMC article.
-
Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.PLoS One. 2015 Apr 2;10(4):e0121136. doi: 10.1371/journal.pone.0121136. eCollection 2015. PLoS One. 2015. PMID: 25837259 Free PMC article.
-
7,8-Dihydroxycoumarin exerts antitumor potential on DMBA-induced mammary carcinogenesis by inhibiting ERα, PR, EGFR, and IGF1R: involvement of MAPK1/2-JNK1/2-Akt pathway.J Physiol Biochem. 2018 May;74(2):223-234. doi: 10.1007/s13105-018-0608-2. Epub 2018 Feb 12. J Physiol Biochem. 2018. PMID: 29435821
-
Influence of CYP19A1 gene expression levels in women with breast cancer: a systematic review of the literature.Clinics (Sao Paulo). 2021 Jun 14;76:e2846. doi: 10.6061/clinics/2021/e2846. eCollection 2021. Clinics (Sao Paulo). 2021. PMID: 34133482 Free PMC article.
-
The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy.Nutrients. 2020 Nov 18;12(11):3537. doi: 10.3390/nu12113537. Nutrients. 2020. PMID: 33217935 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous